Interaction of human plasma membrane proteins and oligodeoxynucleotides

Biochemical Pharmacology

Volumn 55, Issue 8, 1998, Pages 1221-1227

  Corrias, Simona ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense; Oligodeoxynucleotide binding proteins; Oligodeoxynucleotide uptake

Indexed keywords

CYTOSINE DERIVATIVE; DEOXYCYTIDINE; OLIGODEOXYNUCLEOTIDE; THYMIDINE; THYMINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; HUMAN; HUMAN CELL; INHIBITION KINETICS; MEMBRANE BINDING; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION;

BASE COMPOSITION; BINDING, COMPETITIVE; CELL MEMBRANE; HUMANS; KINETICS; MEMBRANE PROTEINS; MOLECULAR WEIGHT; OLIGODEOXYRIBONUCLEOTIDES; PROTEIN BINDING; PROTEIN DENATURATION; TUMOR CELLS, CULTURED;

EID: 0032523024     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00595-9     Document Type: Article

References (35)

1. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science. 261:1993;1004-1012.
2. Gao W-Y, Storm C, Egan W, Cheng Y-C. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol. 43:1992;45-50.
3. Akhtar S, Juliano RL. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 2:1992;139-144.
4. Loke SL, Stein CA, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA. 86:1989;3474-3478.
5. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV. Mechanism of oligonucleotide uptake by cells Involvement of a specific receptor? Proc Natl Acad Sci USA. 86:1989;6454-6458.
6. Stein CA, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R, Rotenberg SA. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry. 32:1993;4855-4861.
7. Goodarzi G, Watabe M, Watabe K. Binding of oligonucleotides to cell membranes at acidic pH. Biochem Biophys Res Commun. 181:1991;1343-1351.
8. Beltinger C, Saragovi HU, Smith RM, LeSauter L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM. Binding, uptake and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest. 95:1995;1814-1823.
9. Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, Klotman PE. Transport of phosphorothioate oligonucleotides in kidney Implications for molecular therapy . Kidney Int. 47:1995;1462-1469.
10. Benimetskaya L, Loike JD, Khaled Z, Loike G, Silverstein SC, Cao L, Khoury JE, Cai T-Q, Stein CA. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nature Med. 3:1997;414-420.
11. Yao G-Q, Corrias S, Cheng Y-C. Identification of two oligodeoxyribonucleotide binding proteins on plasma membrane of human cell lines. Biochem Pharmacol. 51:1996;431-436.
12. Stec WJ, Zon G, Egan W, Stec B. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J Am Chem Soc. 106:1984;6077-6079.
13. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Phytochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16:1988;3209-3221.
14. Maxam A, Gilbert W. Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol. 65:1980;499-560.
15. 2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem. 263:1988;11887-11891.
16. Sobol RW, Suhadolnik RJ, Kumar A, Lee BJ, Hatfield DL, Wilson SH. Localization of a polynucleotide binding region in the HIV-1 reverse transcriptase Implications for primer binding . Biochemistry. 30:1991;10623-10631.
17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
18. 50) of an enzymatic reaction. Biochem Pharmacol. 22:1973;3099-3108.
19. Gao W-Y, Han F-S, Storm C, Egan W, Cheng Y-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerase and RNase H Implications for antisense technology . Mol Pharmacol. 41:1992;223-229.
20. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA. Phosphorothioate oligonucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem. 270:1995;2620-2627.
21. Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA. Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 24:1996;737-745.
22. Maltese J-Y, Sharma HW, Vassilev L, Narayanan R. Sequence context of antisense RelA/NF-κB phosphorothioates determines specifity. Nucleic Acids Res. 23:1995;1146-1151.
23. Krieg AM, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
24. Zhao Q, Temsamani J, Iadarola PL, Jiang Z, Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 51:1996;173-182.
25. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol. 36:1992;983-997.
26. Yamamoto T, Yamamoto S, Kataoka T, Tokunaga T. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer activity is associated with their base length. Antisense Res Dev. 4:1994;119-122.
27. Wyatt JR, Vickers TA, Roberson JL, Buckheit RW Jr, Klimkait T, DeBaets E, Davis PW, Rayner B, Imbach JL, Ecker DJ. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc Natl Acad Sci USA. 91:1994;1356-1360.
28. Rando RF, Ojwang J, Elbaggari A, Reyes GR, Tinder R, McGrath MS, Hogan ME. Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular structures. J Biol Chem. 270:1995;1754-1760.
29. Tondelli L, Colonna FP, Garbesi A, Zanella S, Marongiu ME, Corrias S, Loi AG, La Colla P. Native oligodeoxynucleotide specifically active against human immunodeficiency virus type 1 in vitro A G-quartet driven effect? Antimicrob Agents Chemother. 40:1996;2034-2038.
30. Gao W-Y, Hanes RN, Vazquez-Padua MA, Stein CA, Cohen JS, Cheng Y-C. Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides. Antimicrob Agents Chemother. 34:1990;808-812.
31. Stein CA, Neckers LM, Nair BC, Mumbauer S, Hoke G, Pal R. Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. J Acquir Immune Defic Syndr. 4:1991;686-693.
32. Stein CA, Cleary AM, Yakubov L, Lederman S. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. Antisense Res Dev. 3:1993;19-31.
33. Letsinger RL, Zhang GR, Sun DK, Ikeuchi T, Sarin PS. Cholesteryl-conjugated oligonucleotides Synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture . Proc Natl Acad Sci USA. 86:1989;6553-6556.
34. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 41:1992;1023-1033.
35. Clarenc JP, Degols G, Leonetti JP, Milhaud P, Lebleu B. Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Des. 8:1993;81-94.